Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV immunological agent
- Development stage
- Phase 1
- Lead developer
- West China Hospital of Sichuan University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
The EBV immunological agent is an investigational adoptive cell therapy consisting of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs). Developed by West China Hospital, this therapeutic agent is designed to target and eliminate cells infected with EBV by recognizing specific viral antigens presented on the cell surface. It is primarily being developed for the treatment of EBV-associated lymphoproliferative diseases (EBV-LPD), including chronic active Epstein-Barr virus (CAEBV) infection and post-transplant lymphoproliferative disorders (PTLD). In clinical trial settings, the agent is evaluated as a monotherapy or in combination with immune checkpoint inhibitors like toripalimab to enhance the anti-viral and anti-tumor immune response by overcoming T-cell exhaustion.
- Other names
- EBV-specific cytotoxic T lymphocytesEBV-CTLEBV-specific T cellsEBV-specific T-cell therapy
Beyond the preview
Go deeper on EBV immunological agent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV immunological agent.